Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Antiviral strategies to control calicivirus infections

Jacques Rohayem, Mirko Bergmann, Julia Gebhard, Ernest Gould, Andrea Mattevi, Torsten Ungef, Rolf Hilgenfeld, Johan Neyts

Viral enzymes
Antiviral therapy
Calicivirus

1. The Caliciviridae: emerging pathogens with a high diversity
1.1. Morphology and physicochemical properties
1.2. Classification of the Caliciviridae
1.3. Genome organization of the Caliciviridae
1.4. Multiplication cycle of the Caliciviridae
1.5. Calicivirus infection: epidemiology, transmission and clinical features
1.5.1. Epidemiology of HuCV
1.5.2. Transmission and host resistance

2. Development of antivirals against caliciviruses
2.1. Targeting the attachment and internalization of the virions
2.2. Targeting uncoating and release of the viral genome
2.3. Targeting the viral genomic RNA
2.3.1. The antisense approach
2.3.2. Post-transcriptional silencing using RNA-interference

Abstract
Caliciviridae are human or non-human pathogenic viruses with a high diversity. Some members of the Caliciviridae, i.e. human pathogenic norovirus or rabbit hemorrhagic disease virus (RHDV), are worldwide emerging pathogens. The norovirus is the major cause of viral gastroenteritis worldwide, accounting for about 85% of the outbreaks in Europe between 1995 and 2000. In the United States, 25 million cases of infection are reported each year. Since its emergence in 1984 as an agent of fatal hemorrhagic diseases in rabbits, RHDV has killed millions of rabbits and has been dispersed to all of the inhabitable continents. In view of their successful and apparently increasing emergence, the development of antiviral strategies to control infections due to these viral pathogens has now become an important issue in medicine and veterinary medicine. Antiviral strategies have to be based on an understanding of the epidemiology, transmission, clinical symptoms, viral replication and immunity to infection resulting from infection by these viruses. Here, we provide an overview of the mechanisms underlying calicivirus infection, focusing on the molecular aspects of replication in the host cell. Recent experimental data generated through an international collaboration on structural biology, virology and drug design within the European consortium VIZIER is also presented. Based on this analysis, we propose antiviral strategies that may significantly impact on the epidemiological characteristics of these highly successful viral pathogens.
1. The Caliciviridae: emerging pathogens with a high diversity

The family Caliciviridae includes viruses that cause a broad spectrum of disease in a wide variety of mammalian, avian, and marine animals. This may range from acute gastroenteritis in humans (norovirus and sapovirus) to lethal encephalitis in immune deficient mice (murine norovirus), through haemorrhagic disease in rabbits and upper airway infection in cats (feline calicivirus). Although caliciviruses infect humans and non-humans, thus far there is no evidence for a zoonotic calicivirus reservoir.

1.1. Morphology and physicochemical properties

The caliciviruses (CV) are small round viruses ranging from 27 to 32 nm in diameter. They are some of the smallest animal pathogenic viruses, and were originally referred to as the SRSV (small round structured viruses). Their surface displays a cup-like structure from which the name “calicivirus” was derived (calyx, cup; Fig. 1)(Clarke and Lambda; 2000; Green, 2007).

The cup-like surface of the virions is the capsid protein, consisting of 180 monomers known as virion protein 1 (VP1) which contains two domains: the shell (S), and the protruding (P) domain, being itself subdivided into P1 and P2 subdomains (Chen et al., 2006; Green, 2007). The P2 subdomain is located on the external part of the capsomers, radiating out of the virion surface creating the cup-like shape. Structural comparison of the capsid proteins reveals genus-specificity within the P1 and P2 subdomains (Chen et al., 2004). The P2 subdomain determines viral antigenicity and attachment of virions to cellular receptors (Chakravarty et al., 2005).

The viral capsid plays an important role in the resistance of virions to environmental changes. It resists high concentrations of chlorine, from 3.65 to 6.25 mg/L (residual concentration of 0.5–1.0 mg/L) (Keswick et al., 1985). This concentration significantly reduces the infectivity of other viral agents of gastroenteritis, i.e. poliovirus and rotavirus. Additionally, the viral capsid confers high resistance to physicochemical agents such as heat (60 °C for 30 min), acid (pH 2.7 for 3 h at room temperature), and organic solvents (20% ether at 4 °C for 18 h) (Green et al., 2001). These physicochemical properties contribute significantly to the highly contagious nature of these viruses.

1.2. Classification of the Caliciviridae

Classification of the Caliciviridae relies largely on phylogenetic analysis of the structural and non-structural viral genes, mainly due to the lack of cell culture systems to cultivate the viruses and thus to enable serological tests to be performed. The Caliciviridae comprises four accepted and two tentative genera, including human and non-human pathogenic viruses (Fauquet et al., 2005; Green, 2007; Green et al., 2000; Mayo, 2002). Non-human pathogenic viruses cluster exclusively in the accepted genera Vesivirus, Logovirus, and the tentative genera Becovirus, Nabovirus, and Recovirus, whereas the genera norovirus and sapovirus include both human and non-human pathogens.

Phylogenetic analysis based on the complete VP1 sequence shows that noroviruses cluster tightly in five genogroups. The human pathogenic norovirus belongs to genogroups (G) I, II and IV. Genogroups I and II contain so far 8 and 17 genotypes, respectively (Zheng et al., 2006). The non-human pathogenic strains belong to norovirus GIII and V (Oliver et al., 2007a,b; Park et al., 2007) Genogroup II also contains the bovine and porcine noroviruses (Mauroy et al., 2008; Wang et al., 2007, 2005; Zheng et al., 2006). Genogroup IV contains the feline (lion) and canine noroviruses (Martella et al., 2007, 2008). Genogroup V contains the murine noroviruses (MNV) (Wobus et al., 2006). These MNV are readily propagated in RAW264.7 murine macrophage cells, as well as murine BV-2 cells and various murine cell lines (Cox et al., 2009; Henderson, 2008; Muller et al., 2007; Mumphrey et al., 2007; Thackray et al., 2007; Wobus et al., 2004). Hence, MNV is an interesting surrogate for pathogenicity, multiplicity cycle, and immunity studies that may also reflect properties of noroviruses. Infection in mice is usually asymptomatic. However, in immune deficient mice, i.e. (RAG2/STAT1−/−) MNV type 1 induces lethal encephalitis (Hsu et al., 2007; Karst et al., 2003; Mumphrey et al., 2007). The human pathogenic norovirus (HuNV) is the major cause of human viral gastroenteritis (Wilemelmi et al., 2003) and food-borne non-bacterial gastroenteritis (Lindqvist et al., 2001; Lopman et al., 2002) worldwide. These viruses are highly contagious (Teunis et al., 2008) causing a self-limiting gastroenteritis with a higher prevalence during the winter time in all age groups. They are excreted for weeks after infection in asymptomatic patients (Kirkwood and Streitberg, 2008; Murata et al., 2007; Siebenga et al., 2008).

The genus Sapovirus contains five genogroups. The human pathogenic strains belong to sapovirus GI, IV and V (Farkas et al., 2004; Gallimore et al., 2006; Hansman et al., 2007; Numata et al., 1997; Schuhenecker et al., 2001), whereas the non-human pathogenic strains belong to GI (Fauquet et al., 2005; Green et al., 2000; Guo et al., 2001a). Human pathogenic sapoviruses are distributed globally. They cause viral gastroenteritis in all age groups (Gallimore et al., 2006; Humphrey et al., 1984; Johansson et al., 2005; Lopman et al., 2002; Nakata et al., 1985; Sakuma et al., 1981) including outbreaks in hospitals (Johansson et al., 2005; Simon et al., 1990), child day care centers (Matson et al., 1989), and elderly persons homes (Humphrey et al., 1984). The majority of human pathogenic sapovirus strains belong to GI and GI.
and there is also compelling evidence of circulating non-pathogenic strains that either emerged originally as ancestral lineages of the recognized virulent extant viruses (Moss et al., 2002) or still circulate in wild rabbits as widely divergent non-pathogenic viruses (Forrester et al., 2003). Other non-pathogenic strains arose as variants of virulent virus (Forrester et al., 2007). Other non-pathogenic strains arose as variants of virulent virus (Forrester et al., 2003). The genus Vesivirus includes viruses that infect a broad variety of animals, including felines, reptiles, amphabians, fish and even nematodes (Matson et al., 1996; Smith and Boyt, 1990; Smith et al., 1998). The prototype of this genus is vesicular exanthema of swine virus, VESV, which displays sequence homology with San Miguel Sea Lion Virus (SMSV) (Neill et al., 1998; Smith et al., 1973). Feline calicivirus (FCV), an important veterinary virus, infects domestic and wild cat species causing rhinitis and an ulcerative disease of the upper airways (Radford et al., 2007). Systemic infections with FCV have also been described (Coyne et al., 2006; Foley et al., 2006; Hurley et al., 2004; Pedersen et al., 2000).

The recently recognized tentative genera Beco/Nabovirus and Recovirus include viruses that infect bovines and non-human primates, respectively (Fig. 2). Becovirus (bovine enteric calicivirus) and nabovirus (Newbury agent-1 and NB, Nebraska) have been isolated from calf faeces (Oliver et al., 2006; Park et al., 2008; Simmonds et al., 2008; Smiley et al., 2002). Tulane virus was isolated from the faeces of rhesus macaques, being for the time being the only recognized virus in the genus Recovirus (rhesus enteric calicivirus) (Farkas et al., 2008).

1.3. Genome organization of the Caliciviridae

Caliciviridae genomes consist of a single stranded positive-sense polyadenylated RNA molecule that averages 7500 nucleotides in length and containing either two or three open reading frames, depending on the particular genus (Fig. 3). At the 5′-terminus of the genome, the so-called virion protein genome-linked (VPg) is linked to the viral RNA. The ORF1 encodes non-structural (NS) proteins present in all Caliciviridae in the following order: an N-terminal protein with unknown function (NS1–2), the NTPase (NS3), a small protein of about 20–30 kDa (NS4), the VPg (NS5), the viral protease (NS6), and the viral RNA-dependent RNA polymerase (RdRp, NS7). In the genera Sapovirus, Logovirus and the tentative genera Beco/Nabovirus, the VP1 is encoded within the ORF1, whereas it is encoded in a separate ORF2 in the genera Norovirus, Vesivirus, and Recovirus. The 3′-terminus of the genome, encodes a structural virion protein 2 (VP2), which is followed by an untranslated region, and a poly(A)-tail. Since they share some similarities with picornaviruses, the nomenclature of the non-structural proteins of the Caliciviridae was based on that of the picornaviruses, with the viral polymerase being called 3D-like, the 3C-like viral protease, the VPg, the 3A-like and the 2C-like protein. The increased knowledge on calicivirus replication and genome organization in the last years has led to a new nomenclature where the viral structural proteins are designated NS1/NS2 (N-terminal protein), NS3 (NTPase), NS4, NS5 (VPg), NS6 (protease), NS7 (RNA-dependent RNA polymerase, RdRp). The structural proteins are designated VP1 and VP2. In the sapovirus GI, IV and V, an additional ORF encoding a putative small basic protein has been described (Clarke and Lambden, 2000; Hansman et al., 2005b).

1.4. Multiplication cycle of the Caliciviridae

The multiplication cycles of the Caliciviridae remains poorly understood, mainly because of the limited possibilities of virus cultivation. Indeed, among the six calicivirus genera only the feline calicivirus and the murine norovirus can be easily propagated in cell systems, both being non-human pathogens. For the human pathogenic viruses, there are no suitable in vitro culture systems. Recently, a human norovirus was isolated and viral RNA was propagated for five sequential passages in small epithelial cells (INT-407) cultivated in suspension (Straub et al., 2007). It remains unclear whether or not this system is suitable for isolation of the various norovirus genotypes.

Another approach to studying the molecular biology of calicivirus replication makes use of replicon systems, such as for the Norwalk-like virus (Asanaka et al., 2005; Chang et al., 2006), and porcine enteric calicivirus (Chang et al., 2002, 2004), but also reverse genetics systems for the murine norovirus (Chaudhry et al., 2007; Ward et al., 2007), the feline calicivirus (Sosnovtsev et al., 2005; Thumfart and Meyers, 2002) and Tulane virus (Farkas et al., 2008). Those systems provide future opportunities for comparative analysis of the multiplication cycles of the different genera.
Fig. 2. Classification of the Caliciviridae. Phylogenetic analysis of strains belonging to the so far defined genera (Norovirus, Sapovirus, Lagovirus and Vesivirus) and the two tentative genera Beco/Nabovirus and Recovirus, as indicated. The complete capsid sequence of the strains was aligned with Clustal X (Gibson et al., 1999) and a phylogenetic analysis performed with the neighbour-joining method using PAUP (Swofford, 2002). A bootstrap analysis with 1000 replicates was performed. The bootstrap values are indicated. The strains belonging to non-defined genogroups (GVI, VII, VIII and IX of sapovirus) are indicated by a question mark. The strains FCV/Dresden/2006/GE (Vesivirus, GenBank accession No. DQ424892), and RHDV/Dresden/2006/GE (Lagovirus, GenBank accession no. EF363035) generated within the consortium VIZIER are highlighted in bold. The tentative Genera Recovirus and Beco/Nabovirus are indicated.

FCV has been used during the past two decades as a surrogate to investigate the replication strategy of the Caliciviridae. Many studies have brought insights into the replication of the vesivirus genome (Sosnovtsev and Green, 1995, 2000; Sosnovtsev et al., 2005, 2003, 1998; Sosnovtseva et al., 1999). Lately, additional knowledge has been obtained from studies on the murine norovirus in RAW264.7 murine macrophages in vitro (Sosnovtsev et al., 2006; Wobus et al., 2004, 2006).

Caliciviruses display in terms of genome structure and replication the following common characteristics:

- Naked genomic length RNA is infectious per se, being a positive stranded RNA linked to the VPg at the 5′-terminus and bearing a poly(A)-tail at the 3′-terminus.

- The ORF1 encodes a polyprotein that is further processed co-translationally by the viral protease, leading to at least 6 non-structural proteins involved in the replication of the viral genome.

- The viral RdRp and the VPg play an essential role in the transcription and replication of the genomic, antigenomic RNA and subgenomic RNA.

- The VPg acts as a cap-like structure and interacts with the initiation factors eIF4E and eIF3 (Goodfellow et al., 2005; Daughenbaugh et al., 2006).

- In the noroviruses, vesiviruses and possibly the recoviruses, the structural proteins (VP1 and VP2) are encoded by a subgenomic RNA.

- In the sapoviruses, lagoviruses and possibly the beco/naboviruses, the VP1 is released from the ORF1-encoded polyprotein precursor after cleavage by the viral protease.
Fig. 3. Comparison of the organization of the viral genome of the six calicivirus genera. The complete genome of the following strains is shown: Norovirus GII.4 (Hu/NLV/Dresden174/pUS-NorII/1997/GE strain, GenBank accession no. AY741811), vesivirus (feline calicivirus, FCV/Dresden/2006/GE strain, GenBank accession No. DQ424892), sapovirus G1.1 (Hu/SV/pJG-SapI/DE strain, GenBank accession no. AY694184), and lagovirus (RHDV strain RHDV/Dresden/2006/GE, GenBank accession no. EF363035). The cleavage sites in the viral polyprotein precursor are indicated, as well as the putative molecular weight in kDa (K) of the resulting non-structural proteins.

- The VP2 is a small basic protein that is essential for virion generation (Sosnovtsev et al., 2005).

Schematically, the replication of caliciviruses is thought to contain eight steps (Fig. 4). After attachment of the viral capsid to the cellular receptor, the virion is internalized. The RNA genome is then packaged in endocytic vesicles. The VPg linked to the genome interacts with the cellular translation machinery (the eukaryotic initiation factor 4 (eIF4) complex and the 40S ribosomal subunit (Daughenbaugh et al., 2003, 2006). Translation of the polyprotein and co-translational processing releases the non-structural proteins and their precursors, most importantly the protease-polymerase precursor (NS6-7propol), the protease (NS6pro), the RNA-dependent RNA polymerase (NS7pol), the putative NTPase (NS3NTPase), and the NS4-NS5VPg proteins. These proteins are putatively involved in the enzymatic complex that replicates the genome, and synthesizes the antigenic RNA.

This antigenic RNA is also the template for the genomic RNA, being subsequently translated in mature non-structural proteins. At a given time point in the replication cycle, packaging of the genomic RNA occurs, followed by release of the mature virion from the cell.

1.5. Calicivirus infection: epidemiology, transmission and clinical features

In the following section, we focus on the epidemiology and transmission of the human pathogenic caliciviruses (HuCV, norovirus, and sapovirus), since these viruses are of prime interest for antiviral development.

1.5.1. Epidemiology of HuCV

The HuCVs are one of the most common causes of acute gastroenteritis worldwide, infecting both children and adults. In a recent report from CDC on outbreaks occurring in the USA from 1991 to 2002, norovirus infections were recognized as the most common cause of viral gastroenteritis in all ages in the US, accounting for about 33% of all outbreaks (Lynch et al., 2006; Widdowson et al., 2005). The majority of outbreaks were caused by strains belonging to GII.4 (Koopmans, 2005) suggesting that this genogroup displays preferential features in terms of infectivity and/or transmission efficiency. Alternatively it could reflect increased virulence through enhanced activity of the viral enzymes, or shut-off of cellular host factors in the course of infection. Another important aspect relates to the dynamics of emergence in the noroviruses that correlates tightly with the propensity of disease dissemination through the community and over time, with new strains emerging through mutation and/or recombination. This is mainly supported by the emergence and circulation of norovirus and sapovirus recombinant strains (Gallimore et al., 2004; Jiang et al., 1999a; Katayama et al., 2004; Phan et al., 2006; Reuter et al., 2002; Rohayem et al., 2005; Vinje et al., 2000). Another aspect relates to zoonosis,
HBGAs of high molecular weight may also be found (Huang et al., 2002; Rockx et al., 2005). HBGA are present on the surface of erythrocytes and mucosal epithelial cells or as free oligosaccharides, facilitating their efficient transmission. Human susceptibility to infection by noroviruses is also dependent on the blood group of the individual (A, B, O). The histo-blood group antigens (HBGA) are one of the recognized binding receptors for noroviruses (Hennessy et al., 2003; Hutson et al., 2002; Lindesmith et al., 2003; Marionneau et al., 2002; Rockx et al., 2005). HBGA are present on the surface of erythrocytes and mucosal epithelial cells or as free oligosaccharides in milk, saliva and gut fluid (Marionneau et al., 2001). A recent study underlines the difference of HBGA present in saliva and milk. In human milk, the HBGA are synthesized in higher quantities and display smaller molecular weights and different backbones, although HBGAs of high molecular weight may also be found (Huang et al., 2009). This variability in HBGA content and nature seem to play an important role in modulating the specific binding of human pathogenic norovirus to the HBGA present in saliva and/or milk, and subsequent transmission.

Binding of the VP1 protein to the HBGA has been shown to occur in the P2 subdomain (Cao et al., 2007; Tan et al., 2009, 2003). The differential binding of the P2 subdomain to the HBGA induces a differential susceptibility of humans to infection with the different norovirus genogroups. Binding of the P2 subdomain is modulated by the phenotype of the fucosyl-transferase (FUT) enzyme. The fucosyl-transferase (FUT) conjugates a fucosyl residue to the N-acetyl-glucosamine of the HBGA. Individuals lacking a functional FUT2 enzyme are called non-secretors, as they do not secrete the ABO HBGA in their saliva and the gut fluid. Individuals harboring a functional FUT2 enzyme are called secretors, displaying the A, B or Lewis\textsuperscript{b} phenotypes. This is related to the expression of the enzymes A and B type 1 that conjugate the precursor H type 1 (HBGA) with a glucosyl residue, or through the FUTa1-4 enzyme with a fucosyl residue. Non-secretors (Lewis\textsuperscript{a}) are resistant to infection with the majority of norovirus stains. The non-secretor phenotype is present in about 20% of the European and North American population (Marionneau et al., 2001).

It should however be kept in mind that neither sapovirus genogroup I nor sapovirus CV virus-like particles display such a binding to the ABO HBGA (Shirato-Horikoshi et al., 2006), indicating a different cellular receptor and possibly mechanism of internalization for noroviruses and sapoviruses.

2. Development of antivirals against caliciviruses

Based on our knowledge of the calicivirus genome organization, molecular biology, transmission and replication, potential antiviral strategies are now at least conceivable. In the following section, we will describe potential calicivirus targets for drug development. Possible antiviral approaches using the experimental data on the structure and function of the viral enzymes of replication that was
generated through a successful collaboration within the European consortium VIZIER are also presented.

2.1. Targeting the attachment and internalization of the virions

In the first steps of viral infection, attachment of the virions to the cell surface and interaction with a specific receptor leads to its internalization, followed by uncoating of the viral genome and release into the cytoplasm. To inhibit viral infection of the cell, it may therefore be possible to inhibit binding of the virion and/or internalization and/or release of the viral genome.

Recent work on the feline calicivirus identified the specific receptor for internalization of the virion (Makino et al., 2006). FCV attaches to a 2–6 linked sialic acids, but uses the junctional adhesion molecule 1 (JAM-1), a member of the immunoglobulin superfamily, for internalization in Crandell-Rees feline kidney (CRFK) cells. JAM-1 is expressed in tight junctions in a variety of cells. An anti JAM-1 antibody reduced FCV binding to CRFK cells and thus reduced infectious virus yields (Makino et al., 2006). This advance in the characterization of the specific receptor may represent an interesting antiviral approach by targeting the calicivirus receptor (i.e. JAM-1) using appropriate monoclonal antibodies. However, considering the broad diversity of host cells (enteric cell, respiratory epithelium, dendritic cells, or neuronal cells), important hurdles remain. For instance, the murine norovirus has been recently reported to bind a ganglioside GD1α present on the surface of murine macrophages (Taube et al., 2009). This ganglioside is thought to mediate attachment, but internalization probably requires additional factors, for example, an integrin. A recent study has reported on the involvement of a cholesterol dependent pathway for entry of murine norovirus in RAW264.7 cells, with the clathrin and caveolae pathways being not required for cell entry (Gerondopoulos et al., 2010). Whether or not this phenotype is common to other noroviruses is unclear. It is also unknown whether GD1α is involved alone in binding of the virion or other membrane proteins interact with it. In this case, inhibition of binding to one receptor may lead to inhibition of viral entry in the cell, through a mechanism of steric or allosteric blockade of the interaction between virus and receptor.

There is still little known about the internalization receptor of lagoviruses and sapoviruses. The attachment of HuCV to ABO HBGA, hepagan sulfate, and sialyl-Lewis x (Ryddell et al., 2009; Tamura et al., 2004) has been demonstrated in vitro using virus-like particles (VLPs). The lack of a cell culture system to reproduce the human pathogenic calicivirus, is impeding further work in this subject area.

An interesting antiviral approach may be to block the interaction of the P2-subdomain of norovirus with the HBGA. In a recent study (Feng and Jiang, 2007), Feng et al. screened a compound library using a saliva-based receptor binding assay for blocking the interaction of secreted HBGA and VLPs of the norovirus strain VA387. VLPs display similar antigenic properties to native virions and have been used as tools to investigate virus-host interactions and immune responses in animal models, and for screening potential anti-norovirus candidates (Green et al., 1993; Huang et al., 2003, 2005a; Jiang et al., 1992). In 14 of the 5000 compounds screened, an EC50 value of less than 15 μM was found, and in 2 compounds, an EC50 < 5 μM. Because HuCV are thought to replicate in intestinal cells, inhibition of attachment of HuCV to the HBGA receptor may represent an interesting strategy to inhibit infection of the cell. If applied early in the course of infection, it may also block propagation of the virions within the tissue. This kind of treatment may be suitable in a preventive set-up in the course of spatial limited outbreaks occurring for example on cruise ships.

A similar approach relies on trapping the norovirus in glycosylated hydrogels (Zhang et al., 2006). The trapping capacity of hydrogel was estimated to be about 24 μg VLPs per mg. Although promising, this approach is more suitable to prevent transmission of norovirus from person-to-person.

Because, in contrast to noroviruses, the human pathogenic sapoviruses do not rely on attachment to HBGA, additional data concerning virus binding and entry will be needed to bring the proof-of-principle for an attachment-inhibition-based antiviral approach in caliciviruses.

2.2. Targeting uncoating and release of the viral genome

Many viruses enter the cell and the cytoplasm through endocytic vesicles (Pelkmans and Helenius, 2003; Smith and Helenius, 2004). In mammalian cells, various endocytosis pathways have been described: macropinocytosis, phagocytosis, endocytosis via caveolae/lipid rafts, and clathrin-mediated endocytosis. Following endocytosis, uncoating of the viral genome may depend on lowering of the pH in the endocytic vesicles. The pH change leads to conformational change of the viral capsid, with exposition of motives located on the subdomains (Bhella et al., 2008). In an experimental set-up, the low pH-environment of the endosome induced structural changes of the FCV capsid leading to release of the viral genomic RNA (Stuart and Brown, 2006). Hence, a possible antiviral approach may be to use compounds or short peptides that inhibit rearrangements of the viral surface related to pH change. Another approach may rely on inducing pH-modifications in the different compartments of the cell, and subsequently the intra-cellular pH-gradient. Two different compounds are known to inhibit the reduction of the endosomal pH: a weak basic compound (chloroquine), and a macrolide antibiotic that selectively inhibits the vacular type of vesicular proton ATPase (Bafilomycin A1). Bafilomycin A1 and chloroquine increase in a concentration-dependent manner the pH of the endosomal compartment and may be used to inhibit uncoating of the viral genome by inhibiting acidification of the endosome. Interestingly, chloroquine and Bafilomycin A1 inhibit FCV infectivity in vitro (Stuart and Brown, 2006). Moreover, Chlorpromazine, a compound known to inhibit clathrin-mediated endocytosis, inhibits internalization of FCV in vitro (Stuart and Brown, 2006). It remains unclear whether or not other calicviruses display similar entry and uncoating mechanisms. Recent data on murine norovirus revealed that infection of murine RAW264.7 was not inhibited by reagents that raise endosomal pH (Gerondopoulos et al., 2010). Nevertheless, and because all three substances are commercially available, they represent a promising approach to control infection by FCV.

2.3. Targeting the viral genomic RNA

After its release into the cytoplasm, the viral mRNA is recruited to the endoplasmic reticulum for translation to produce the viral polyprotein. At this stage, inhibition of the function of the whole genomic RNA and/or parts of it stops viral replication. To this end, two strategies have been developed in Caliciviridae, both making use of nucleic acids targeting the 5'-end and/or the 3'-end of the genome. Comparative analysis of the structural features of members of the Caliciviridae has shown that all strains display stem-loops and hairpin structures at the 5'-terminus and the 3'-terminus of the viral genome, respectively (Simmonds et al., 2008).

Using an experimental approach based on the murine norovirus reverse genetic system, disruption of the 5'-stem loops or the 3'-hairpins strongly impaired viral replication in RAW264.7 murine macrophages in vitro (Simmonds et al., 2008). Moreover, a polyipyrimidine tract located at the 3'-terminus of the genome has been incriminated in regulating viral fitness and virulence in a small animal model of infection (Bailey et al., 2010a). This indicates that those structures play an important role in the infectivity of the MNV.
Both regions are preferentially targeted by nucleic acid based approaches as both bear highly conserved sequences within genera (i.e. in FCV, Table 1). The nucleic acid-based strategies are the antisense approach and the post-transcriptional gene silencing (or RNA-interference) approach. There are important prerequisites for the successful implementation of a nucleic acid-based antiviral approach. First, the target sequence has to be involved in viral replication. Additionally, it must be accessible for oligonucleotide hybridization, and most importantly when dealing with RNA viruses with high genomic variability it must be conserved among different viral species. Hence, the regions that are preferentially targeted reside within the 5′- and 3′-UTRs of the viral genome, where conserved regions may span entire genera.

### 2.3.1. The antisense approach

The antisense approach uses DNA-oligonucleotides targeting conserved regions of the viral genome. It has been applied in various models of viral infections with positive-stranded and negative-stranded RNA viruses (Gabriel et al., 2008; Lupfer et al., 2008; Paessler et al., 2008; Stein et al., 2008; Stein et al., 2008; Stein and Shi, 2008).

In the Caliciviridae, peptide-linked phosphorodiamidate morpholino oligomers (PPMOS) targeting a sequence near the 5′-UTR of the murine norovirus genome were effective in reducing translation of viral proteins in vitro (Bok et al., 2008). Our preliminary investigations have made use of the PPMO-approach to inhibit multiplication of the feline calicivirus in vitro. Seven PPMOs (kindly provided by Dr. David Stein, AVI Biopharma) were designed to target the viral genome in particular the 5′-UTR or the 3′-UTR of the feline calicivirus genome (Table 2). In a cell proliferation assay, the lowest EC50 observed was 20.4 μM, with a selectivity index of 9.8 (Table 3).

Phosphorodiamidate morpholino oligomers (PMO) targeting the 5′-UTR of the FCV genome were used in 3 clinical trials relating to FCV outbreaks. From day 1 of infection, PMOs were administered parenterally to 112 kittens for 7 days in different dosages (0.7–5.0 mg/kg). The PMO displayed a dose-dependent effect. Of the 59 animals treated, 47 survived the infection. In comparison, in 31 animals not treated with PMO, only 3 survived the infection (Smith et al., 2008).

### Table 1

Sequences of the 5′-UTR and 3′-UTR of feline calicivirus strains displaying 100% identity to the FCV/Dresden/2006/GE strain (GenBank accession no. DQ424892) used for the antiviral nucleic acid based approach. The nucleotide positions as well as the GenBank accession no. of the strains are indicated.

| GenBank accession no. of the FCV strains | 5′-UTR (nt position) | 3′-UTR (nt position) |
|-----------------------------------------|----------------------|----------------------|
| M86379                                  | 1–63                 | 7536–7570            |
| AY560113                                | 1–57                 | 7533–7561            |
| AY560114                                | 1–57                 | 7536–7570            |
| AY560115                                | 1–63                 | 7542–7573            |
| AY560116                                | 1–50                 | 7542–7573            |
| AY560117                                | 1–57                 | 7542–7573            |
| AY560118                                | 1–56                 | 7545–7594            |
| L40021                                  | 1–63                 | 7542–7585            |
| NC001481                                | 1–63                 | 7542–7585            |

Although preliminary, these experimental data indicate that PPMOs may represent an interesting approach for treatment of calicivirus infections.

### Table 2

Sequence characteristics of the oligonucleotides used for antiviral nucleic acid based approach.

| Oligonucleotide | Sequence (5′–3′ orientation) | Length (nt) | Target (nt position) |
|-----------------|------------------------------|-------------|----------------------|
| PPMO-1          | GAC ATT GTC TCA AAT TTC TTT TAC | 24          | 1–24                 |
| PPMO-2          | GCA CAT GCT CAA ACT TCG AAC AC | 23          | 5294–5313            |
| PPMO-3          | CCC ATG TAG GAG GCA GTA AGA GG | 23          | 7237–7259            |
| PPMO-4          | CCC TCT TGT TAG GCC CTA CAG CGG | 24          | 1497–1520            |
| PPMO-5          | GTA AAA GAA ATT TCA GAC AAT GTC | 24          | 1–24                 |
| PPMO-6          | GCC GTC TAG GCG CTA ACC CCA GIC | 24          | 7658–7680            |
| PPMO-7          | TGC TCT GTC TAC AGT AGT GCA TCT | 22          | 6159–6180            |
| siR19           | ACU CUG AGG UUC CUG CUCU ATT | 21          | 29–47                |
| siR20           | UUA GCA CGA AGG UCA GAG UTT | 21          | 5321–5339            |
In particular in the case of emerging viruses with high genomic and post-transcriptional gene silencing may be a potential antiviral approach through targeting of the viral genome. This approach offers many advantages that may render it attractive despite the potential antiviral molecules, possibly causing steric blocking variability. Nevertheless, several pre-requisites have to be fulfilled before its implementation as a therapeutic tool. Clearly, two major hurdles would be its bioavailability and its specific delivery to the infected cells.

2.4. Targeting the translation of the viral genome

Translation of the viral genome is the first step in the replicative cycle of the positive-sense RNA viruses. Initiation of translation has been reported to be dependent on the interaction of the VPg with cellular translation factors, such as the elf4F initiation complex. This complex is a key player in the initiation of translation of eukaryotic mRNA. It assembles the pre-initiation complex to the mRNA via its interaction with the cap-structure and the elf3 (Gingras et al., 1999; Kapp and Lorsch, 2004). The elf4F complex consists of an RNA helicase (elf4A), a factor directly interacting with the cap-structure of the mRNA (elf4E), and a binding protein (elf4G) to other cellular translation modulators such as the poly(A)-binding protein (PABP) and elf3.

In FCV and MNV, the VPg interacts with the initiation factors elf4E and elf3, whereas the VPg of NV interacts with the elf4E (Goodfellow et al., 2005). In both FCV and MNV, translation of the polyprotein precursor depends on the presence of a functional component of the elf4F complex, the RNA helicase. Indeed, treatment of FCV infected cells with a small molecule inhibitor of elf4A (hippuristanol) blocks translation of viral proteins. Hippuristanol interacts with the C-terminus of elf4A with subsequent inhibition of its NTPase hence helicase activity (Bordeleau et al., 2006). Importantly, hippuristanol is expected to have toxic effects on the cells due to the inhibition of host cell – as well as calicivirus – protein synthesis.

In a similar way, pateamine stimulates both helicase and NTPase activities of elf4A, dysregulating its function within the translation complex (Bordeleau et al., 2006). In this sense, using inhibitors of components of the elf4F complex, i.e. hippuristanol (Bordeleau et al., 2006), or dysregulators of the elf4A function, i.e. pateamine (Low et al., 2005) is a promising approach. Another important regulator of translation is the interaction of the 5′- and 3′-untranslated regions of the viral genome with cellular host factors involved in protein translation. At both ends of the calicivirus genome, untranslated regions (UTR) of variable size between genogroups and genera are present. Although experimental evidence for the direct interaction of these structures with the translation machinery is still lacking, disruption of the structures in a model of infection in vitro led to strong impairment of the replication of murine norovirus. These data support the concept of an important role for the structured termini of the calicivirus genome in the viral multiplication cycle. These properties of the calicivirus genome being highly structured are very common amongst many other positive-strand RNA viruses (Goodfellow et al., 2000; Haasnoot et al., 2002) such as picornaviruses (i.e. the CRE-element (Goodfellow et al., 2003), or the IRES (Pelletier and Sonenberg, 1988; Xiang et al., 1995)) or flaviviruses (Tsukiyama-Kohara et al., 1992; Wang et al., 1993; Gritsun and Gould, 2006a,b, 2007; Proustki et al., 1997a,b, 1999).

The 5′- and 3′-UTR of the viral genomes are highly structured sequences that fold in a functional conformation. In order to ensure appropriate folding and subsequent interaction with viral structural and non-structural proteins, cellular chaperones such as the polypyrimidine tract-binding protein (PTB) are required (Herschlag, 1995; Treiber and Williamson, 2001). The PTB is expressed in the nucleus and cytoplasm acting as a regulator of splicing pathways (Ghetti et al., 1992; Lin and Patton, 1995). The PTB was postulated to work as a chaperone for the viral genomic RNA, implicated in folding to secondary structures located at the 5′-terminus of the genome. In FCV, the PTB interacts specifically

**Fig. 5.** Inhibition of calicivirus particle formation in CRFK-monolayer after infection with the FCV/Dresden/2006/GE strain (GenBank accession No. DQ424892). Two siRNA (siR19 and siR20) targeting conserved sequences in the 5′-UTR and 3′-UTR, respectively, were used. The siRNA (330 nM) was transfected into the CRFK cells 5 h prior to infection with FCV. Plaque assays were performed as described by others (Gray, 1999), yielding a viral titre of 500 PFU/ml. The siRNA completely inhibited viral multiplication in the CRFK cells.
with sequences located at the 5′-UTR of the genome (Karakasilioti et al., 2006), and is required for multiplication of the FCV in host cells. In murine norovirus, the PTB binds to a polypyrimidine tract located within the 3′-UTR of the viral genome (Bailey et al., 2010a). This interaction was reported not to be essential for virus replication, although being an important regulator of viral fitness and virulence (Bailey et al., 2010a).

Host cell factors such as Unr (Boussada et al., 2003), poly(rC)-binding protein (PCBP) (Parsley et al., 1997), La autoantigen (Meerovitch et al., 1993), hnRNPA1 (Huang and Lai, 2001) and poly(A)-binding protein (PABP) interact with the viral genome of a variety of RNA viruses. The host cellular factors modulate translation and processing of the viral polyproteins, but also the translation of host cell mRNA. In human pathogenic Norwalk virus, PTB (Gutierrez-Escolano et al., 2003), La autoantigen, hnRNPA and PCB-2 interact with both the 5′-UTR and the 3′-UTR (for La and PTB) (Gutierrez-Escolano et al., 2003), although no functional roles of those proteins in norovirus replication have been described so far.

Taken together, this knowledge on translation initiation in the Caliciviridae offers interesting possibilities (i.e. peptides, nucleic acids) to target the interaction of the viral genome and/or the VPg with cellular host factors of translation, with subsequent inhibition of viral protein synthesis.

2.5. Targeting replicative viral enzymes

2.5.1. The viral chymotrypsin-like protease

The calicivirus chymotrypsin-like protease plays a central role in viral replication. The molecular mechanisms underlying the catalytic activity and specificity of the norovirus, sapovirus, murine norovirus and feline calicivirus protease have been extensively investigated. Knowledge on the regulation of calicivirus polyprotein processing is an important prerequisite for the development of antiviral drugs to control calicivirus infection.

The viral protease is involved in early steps of replication. Its active form is the viral protein NS6pro, or a protein precursor consisting of the viral protease and polymerase NS6proNS7pol. The cleavage pattern of the calicivirus polyprotein precursor by the viral protease has been investigated both in cell-free expression systems (Belliot et al., 2003; Liu et al., 1999; Seah et al., 2003) and in mammalian cells (Chang et al., 2006; Seah et al., 1999, 2003; Sosnovtsev et al., 2006). Processing of human Norwalk virus in Huh-7 cells (Chang et al., 2006) and of a murine norovirus strain in the macrophage-like cell line RAW264.7 (Sosnovtsev et al., 2006) have shown that both the NS6proNS7pol precursor and the NS6pro are present in infected cells. A similar observation was reported for a related non-human pathogenic calicivirus strain, the rabbit hemorrhagic disease virus (RHDV, genus Lagovirus). However, in another human pathogenic calicivirus, the sapovirus (SV), NS6proNS7pol is the only protein detected in a cell-free system (Oka et al., 2005a,b). In the case of the pathogenic feline calicivirus (FCV), the NS6proNS7pol precursor is detected in mammalian cells (Sosnovtsev et al., 2002, 1998; Sosnovtseva et al., 1999). In accordance with our observations (Scheffler et al., 2007), evidence for autocatalytic cleavage of norovirus NS6pro from the polyprotein precursor has been presented (Belliot et al., 2003; Chang et al., 2006; Liu et al., 1999; Seah et al., 1999; Sosnovtsev et al., 2006).

The cleavage specificity observed is explained by studies on the structure of the norovirus protease (Nakamura et al., 2005; Zeitler et al., 2006) and sapovirus protease (Robel et al., 2008). In the sapovirus NS6pro, the catalytic triad consists of Cys116-His31-Glu52. His131 is located at the bottom of the S1 pocket. Its role is to interact with the P1 side chain of the substrate, as observed in norovirus NS6pro (see below). Another His residue, His157 plays an important role by holding Glu52 in its proper position in the triad. This feature does not exist in norovirus 3C-like protease.

The crystal structure of norovirus NS6pro has revealed that five residues govern the specificity of substrate binding to the protease: His157 and Ala160 in the S1 pocket, and Arg112, Arg113 and Val114 in the S2 pocket (Nakamura et al., 2005). In the S1 pocket, the His157 residue interacts with the Glu (P1) residue at the scissile bond (Zeitler et al., 2006). His157 is important for substrate binding since its mutation severely reduces the activity of NS6pro (Sosnovtsev et al., 2002). In other RNA viruses (human rhinovirus, hepatitis A virus, poliovirus, and coronavirus), similar observations were made, with the His at the S1 site interacting through its imidazole ring with the carboxamide chains of the P1 residue (Allaire et al., 1994; Anand et al., 2002, 2003; Bergmann et al., 1997; Matthews et al., 1994; Mosimann et al., 1997; Yang et al., 2003). Furthermore, the presence of a small residue (Gly or Ala) at the P1′ positions of the scissile bonds in norovirus polyprotein is consistent with the limited volume allowed for the P1′ residue in the S1 pocket of norovirus protease (Nakamura et al., 2005). In contrast, the S2 hydrophobic pocket of the norovirus protease is large enough to accommodate the side chain of a bulky hydrophobic amino acid such as Phe, Met, or Leu (Nakamura et al., 2005). Similarly, the binding sites for the P3 and P4 residues in norovirus NS6pro are reported to be large enough to accommodate residues of various sizes (i.e., Ser, Gly, His, or Thr in the P3 pocket, and Phe, Met, Ala, or Leu in the P4 pocket) (Nakamura et al., 2005).

Because of the specificity of cleavage of the scissile bonds of the polyprotein of the various calicivirus genera, peptidomimetics or substrate-like peptides may constitute an interesting strategy for the inhibition of viral replication. Another possible approach may be to use inhibitors that block the protease active site. For the implementation of such an approach at least two important barriers have to be crossed. These are (i) the large size of the peptidic compounds, and their possible poor bioavailability and (ii) the limited in vivo stability of peptides. Nevertheless, because of the extensive knowledge generated on the structure and function of the chymotrypsin-like protease, targeting the viral protease may be one of the most promising approaches to inhibit calicivirus replication.

2.5.2. The RNA-dependent RNA polymerase

The RdRp is involved in synthesis of the genomic, subgenomic and antigenomic RNA of the calicivirus. Structural analysis of the norovirus, sapovirus and RHDV RdRp has revealed a right-hand structure typical for template-dependent polymerases (Biswal et al., 2005; Choi et al., 2004; Ferrer-Orta et al., 2004; Ng et al., 2002, 2004). Interestingly, structural similarities that exist in the shortened loop section of RHDV, sapovirus and norovirus NS7pol (Ng et al., 2002) suggest similar mechanisms for activation of RNA elongation in Caliciviridae. Nevertheless, sapovirus NS7pol displays functional similarities to norovirus NS7pol, but not to vesiviruses (FCV) and lagoviruses (RHDV) RdRp. This relates mainly to the ability of both sapovirus and norovirus NS7pol to initiate RNA synthesis de novo on heteropolymeric templates, with a primer-dependent initiation of RNA synthesis on homopolymeric templates, and a terminal transferase activity with a preference for CTP (Rohayem et al., 2006b; Fullerton et al., 2007).

The potential strategies to inhibit the calicivirus RdRp fall in two categories: nucleoside analogue inhibitors and non-nucleoside inhibitors.
described (Fullerton et al., 2007). The mean of three independent experiments are shown. CPM, counts per minute. Each elongated by the RdRp, leading to chain termination. In a pre-

They are then incorporated in the polymerized nucleic acid chain and undergo phosphorylation by triphosphate, giving nucleotides. sapovirus RNA-dependent RNA polymerase NS7pol was determined as previously

norovirus RNA-dependent RNA polymerase was determined as previously RNA polymerases by nucleoside analogues. (A) Assessment of the activity of norovirus and sapovirus RNA-dependent RNA polymerase. As shown in Fig. 6, both the activity of the HuCV polymerases. As shown in Fig. 6, both the 2′-arauridine-5′-triphosphate; 3′-deoxyuridine-5′-triphosphate. 2′-O-Methyl-UTP, 2′-O-methyluridine-5′-triphosphate. 2′-O-Methyl-UTP, 2′-O-methyluridine-5′-triphosphate. 2′-deoxy-UTP, 3′-deoxyuridine-5′-triphosphate. 2′-O-Methyl-UTP, 2′-O-methyluridine-5′-triphosphate. The mean and the standard error of the mean of three independent experiments are shown. CPM, counts per minute. Each of the compounds was incubated at a concentration of 50 μM.

Nucleoside analogs all display similar mechanisms of inhibition of the RdRp activity. The nucleosides penetrate the cell and undergo phosphorylation by triphosphate, giving nucleotides. They are then incorporated in the polymerized nucleic acid chain elongated by the RdRp, leading to chain termination. In a preliminary investigation and in order to validate both polymerases of the HuCV as targets for antiviral design, we have tested five different nucleoside analogs for their potential as inhibitors of the activity of the HuCV polymerases. As shown in Fig. 6, both the 2′-arauridine-5′-triphosphate (TriLink technologies) and the 3′-deoxyuridine-5′-triphosphate (TriLink technologies) displayed potent inhibitor activities against the HuCV polymerases at a concentration of 50 μM. In contrast, other nucleoside analogs did not show any activity against the HuCV polymerase. This provisional data is in favor of using the HuCV RNA-dependent RNA polymerase as a target for the development of antiviral drugs (Fig. 6).

Another substance of interest is ribavirin. Ribavirin (1-α-D-ribofuranosyl-1,2,4-triazole-3-carboxamide) efficiently inhibits norovirus replication in vitro (Chang and George, 2007). Ribavirin is a synthetic guanosine analogue, has a broad range of antiviral activity against RNA but also DNA viruses. In the NV replicon system, Ribavirin was reported to display an EC50 of 40 μM (Chang and George, 2007). This value was 100 μM when MNV-infected RAW264.7 cells were treated (Chang and George, 2007). In feline calicivirus, Ribavirin was however not effective in vivo (Povey, 1978a,b). Although the experimental data in vitro is encouraging, and because Ribavirin has a lot of adverse effects and a very narrow therapeutic index, it is at this time point not suitable for the treatment of a disease such as viral gastroenteritis with almost no lethal outcome.

2.5.3. The VPg

The VPg is putatively linked to the genomic RNA in caliciviruses, although experimental evidence of this linkage is still lacking for non-human pathogenic caliciviruses. The VPg is involved through uridylylation in a protein-primed dependent initiation of RNA synthesis of antigenomic and presumably genomic RNA. Uridylylation is thought to occur at tyrosine 24 in the protein, as shown through mutation analysis in the FCV reverse genetics system (Mitra et al., 2004). Uridylylation has been experimentally proven for noroviruses (Belliot et al., 2008; Rohayem et al., 2006b), and for lagoviruses (Machin et al., 2001).

Uridylylation is thought to involve the viral RdRp, the VPg, as well as the polyadenylated viral genome. Whether or not the antigenomic viral RNA is involved remains unknown, but by analogy with poliovirus it could potentially be.

Prevention of uridylylation of the viral genome could also be an interesting antiviral approach, through inhibition of the interaction of the VPg with the RdRp, and/or with the viral genome, resulting in the shut-off of synthesis of the viral genomic RNA.

2.5.4. The NTPase

Another possible target for antiviral therapy is the calicivirus NTPase. The NTPase (NS3) displays the canonical motifs of viral NTPases as described for picornaviruses and flaviviruses, forinstance. The occurrence of the three motives A (GXXGXGKS/T), B (DD/E) and C (KKXXFXXXXTXS/TTN) classifies the calicivirus NS3NTPase in the superfamily 3 of RNA helicases (Pfister and Wimmer, 2001), although experimental evidence in vitro and in cell culture for its putative RNA unwinding activity is still lacking. The recombinant NS3NTPase displays NTPase activity in vitro, but does not bind RNA, nor does it unwind RNA – RNA or RNA – DNA duplexes (Pfister and Wimmer, 2001). Here, future experimental evidence may help in designing innovative antiviral strategies targeting this important enzyme of calicivirus replication.

By analogy with the flavivirus NTPase/helicase that has been extensively studied and characterized functionally and structurally, inhibitors of the NTPase/helicase may act by (i) competitive inhibition and blockade of the NTP binding site, or (ii) by conformational changes through immobilization of the switch region, (iii) by competitive inhibition of RNA binding, or (iv) by inhibition of unwinding via steric blockade of translocation of the NTPase/helicase along the template RNA.

2.6. Targeting assembly of the replication complex

The viral enzymes of replication interact in a complex of multiple components, constituting the replication complex. This complex may be transient, or relatively stable; and the ability of the viral enzyme to interact with any one partner of interest may be significantly influenced by other complex members. In caliciviruses, the replication complex is predicted to involve mainly three viral enzymes: the RNA-dependent RNA polymerase, the viral protease, and the NTPase/helicase. In addition to the viral genomic/antigenomic and/or subgenomic/anti-subgenomic RNA, structural viral proteins may be included, but also the VPg, or the N-terminal protein. Experimental data using noroviruses has shown that the N-terminal protein interacts in a vesicular complex with the VAP-A-Protein (vesicle-associated membrane protein-associated protein A) leading to inhibition of intracellular protein trafficking (Ettyebei and Hardy, 2003). In FCV, the interaction of NS2 with NS3NTPase, NS4, NS5VPg and NS6-7propol has been demonstrated in vitro (Kaiser et al., 2006). The FCV NS6-7propol was also reported to interact with the NS5VPg, interacting itself with the structural protein VP1 (Kaiser et al., 2006).

So far, the determinants of assembly and structure of the replication complex, as well as at its role in regulating the life cycle of the
virus remain poorly understood. Moreover, our recent results generated within the VIZIER-Consortium indicate that small molecules inhibiting viral replication in mammalian cells might possibly target the replication complex, specifically the interaction of the viral enzymes within the complex. The effect of small molecules would mainly be to destabilize the complex, subsequently inhibiting the replication of the viral genome, hence the multiplication of the virus within the cells. Therefore, knowledge of the functional and structural determinants of interaction and assembly of the replication complex could provide a cornerstone for developing new antiviral strategies.

Our work within the VIZIER-Consortium has contributed to decipher the activity of the norovirus RdRp, showing that the active form of the viral RdRp of noroviruses is a homodimer displaying a positive cooperativity (Hogbom et al., 2009). Our results also show that homodimerization of norovirus NS7 monomers is concentration-dependent, and that the apparent Kd of homodimerization lies within the nM range. Moreover, the monomers display a positive cooperativity in vitro. Similar observations on the NS6/7propel of FCV cultivated in cell systems were reported (Kaiser et al., 2006).

Here, the development of antiviral strategies aiming at destabilizing the interaction between the NS7propel monomers is of interest. Another approach may rely on targeting the interaction of the structural proteins within the replication complex.

2.7. Targeting the post-replicative steps

Following replication of the viral genome, further steps such as the assembly of the capsid protein, budding of the virions in the endoplasmic reticulum, transport and maturation of the virions in the ER and the Golgi complex, and vesicle fusion lead to release of the mature virions. Recent experimental data on the feline calicivirus has shown that upon infection, 3 viral non-structural proteins (p32, p30, and p39) co-localize to the ER, leading to a morphological changes of the ER membranes (Bailey et al., 2010b). Our results also show that homodimerization of norovirus NS7 monomers is concentration-dependent, and that the apparent Kd of homodimerization lies within the nM range. Moreover, the monomers display a positive cooperativity in vitro. Similar observations on the NS6/7propel of FCV cultivated in cell systems were reported (Kaiser et al., 2006).

Following replication of the viral genome, further steps such as the assembly of the capsid protein, budding of the virions in the endoplasmic reticulum, transport and maturation of the virions in the ER and the Golgi complex, and vesicle fusion lead to release of the mature virions. Recent experimental data on the feline calicivirus has shown that upon infection, 3 viral non-structural proteins (p32, p30, and p39) co-localize to the ER, leading to a morphological changes of the ER membranes (Bailey et al., 2010b). It remains however unclear whether these rearrangements are incriminated in the assembly of the replication complex, or not.

For other caliciviruses, these steps are poorly understood. Therefore, antiviral strategies targeting the post-replicative steps of the genome will not be developed, until substantial knowledge of those steps is generated.

3. Vaccines and other approaches

Immunity to human pathogenic caliciviruses is very poorly understood, mainly because of a lack of cell culture systems to investigate neutralization of virus multiplication by serum or intestinal secretory antibodies. However, volunteer challenge studies have established that human pathogenic caliciviruses and particularly noroviruses induce two forms of immunity: a short-term and a long-term immunity (Atmar et al., 2008; Parrino et al., 1977; Wyatt et al., 1974). Short-term immunity is virus-specific; individuals infected with a norovirus strain are resistant to re-infection with the same strain for up to 14 weeks following primary infection. Long-term immunity, in contrast, confers resistance to infection that lasts about 34 months following primary infection. Another interesting aspect relates to the type of cell-mediated immunity following infection with the human pathogenic calicivirus, i.e. norovirus. Volunteer challenge studies have shown that the cell-mediated immune response to norovirus infection displays a Th-1 dominant pattern (Lindesmith et al., 2005). In animal models, important insights into norovirus immunity to infection as well as pathogenesis have been generated recently based on the surrogate MNV (Liu et al., 2009; Bailey et al., 2008; McCartney et al., 2008; Mumphrey et al., 2007).

Virus-like particles that mimic structurally and antigenically the native capsid protein have been extensively used to explore the function and reactivity of noroviruses and sapoviruses (Guo et al., 2001b; Hansman et al., 2005a, 2006; Jiang et al., 1999b; Oka et al., 2006). VLPs are produced to relatively high yields in baculovirus recombinant expression systems or in the human endothelial kidney cell line HEK-293T (Taufe et al., 2005) assembling in the absence of the VP2, although the VP2 seems to enhance VLPs stability (Green et al., 1997; Jiang et al., 1992). Furthermore, feeding of volunteers and laboratory animals with norovirus virus-like particles generated in tomato plants (Huang et al., 2005b) or potato plants (Tackett et al., 2000) led to an immune response (IgG and IgA) with variable intensity, depending on the adjuvant used. These and other previous data on vaccination (Guerrero et al., 2001; Ball et al., 1998) control infection by human caliciviruses is encouraging and deserves further development and evaluation.

For FCV, a vaccine is available (Radford et al., 2006). The development of an efficient vaccine was possible because FCV can be amplified in CRFK cells, and a small model (felines) is also available. FCV vaccines use either attenuated or inactivated virus. Furthermore, dual-strain FCV vaccines consisting of virulent and attenuated strains have already been successfully implemented in clinical trials (Huang et al., 2010). VLPs have also been effective in generating neutralizing antibodies in rabbits against various FCV strains, indicating that they could represent an interesting alternative to attenuated or inactivated viruses for production of FCV vaccines (Di Martino et al., 2007).

In a recent study (LoBue et al., 2006), multivalent norovirus VLPs adjuvanted with aliphavirus or CpG DNA were administrated to mice. The VLPs induced a mucosal and systemic immune response, and a reduction of viral titer in immunized mice following MNV challenge. Sera from immunized mice proved to be protective against MNV when transferred to immunodeficient mice. Similarly, VLPs representing RHDV and bearing a T cell epitope from ovalbumin were shown to be able to elicit a T cell immune response in dendritic cells, and to induce a cellular immune response in mice (Crisci et al., 2009).

These data are encouraging and highlight the potential of the VLP-based approach for the development of calicivirus vaccines. Another experimental approach is based on inhibition of norovirus replication by interferon. Using a reverse genetics system for NV, Chang and George (2007) have shown that IFN-α and IFN-γ inhibit translation and replication of calicivirus in a dose-dependent manner in vitro. As a correlate, the susceptibility of MNV to IFN was observed in vitro (Changotra et al., 2009; Wobus et al., 2004) and also in vivo (Karst et al., 2003). Although the observed EC50 was in the micromolar range, these data are of interest in the context of the antiviral effect of IFN on caliciviruses.

A more general approach for treatment of human pathogenic calicivirus infection has relied on the substitution of electrolytes and water loss by per os or per enteral rehydration, representing hence a symptomatic treatment of the infection (Anderson, 2010), but not an antiviral approach. The positive effect of nitazoxanide in controlling norovirus infections has also been described (Rossignol and El-Gohary, 2006).

4. Conclusions and future prospects

The possibility to cultivate members of three genera, noroviruses, vesiviruses, and reoviruses within the family Caliciviridae, is an important step towards better understanding of the replication cycle of these viruses and also the development of effective antiviral strategies. Nevertheless, there is clearly a
need for culture systems to propagate the human pathogenic variants of noroviruses and sapoviruses in mammalian cells. This has hampered the development of antiviral approaches as well as vaccines, but also the in-depth study of the pathogenicity of the human pathogenic calicivirus, accounting for the slow progress in the field.

One of the potential problems caused by the treatment of calicivirus infections will be, as observed for other RNA viruses with a positive stranded genome, the emergence of drug resistance. The major problem lies in the high genomical variability of the strains in particular for human pathogenic noroviruses, as well as the accelerating emergence of new variants. Therefore, antiviral strategies should aim at targeting conserved regions in the viral genome and possibly not exposed to immunological pressure leading to immune escape. Because of the short duration of the disease, treatment of calicivirus infection may focus on the containment of the infection in the context of outbreaks, as well as long-term shedding of the virus after infection, as observed following infection with noroviruses.

Acknowledgements

This work was supported by the European Consortium “Vizier” (www.vizier-europe.org) as well as the Jürgen Manft Stiftung (for Mirko Bergmann, Julia Gebhardt and Jacques Rohayem).

References

Allaire, M., Chernia, M.M., Malcolm, B.A., James, M.N., 1994. Picornaviral 3C cysteine proteinases have a fold similar to chymotrypsin-like serine proteinases. Nature 372, 72–76.
Anand, K., Palm, G.J., Mesters, J.R., Siddell, S.G., Ziebuhr, J., Hilgenfeld, R., 2002. Structure of coronavirus main proteinase reveals combination of a chymotrypsin fold with an extra alpha-helical domain. EMBO J. 21, 3213–3224.
Anand, K., Ziebuhr, J., Wadhwani, P., Mesters, J.R., Hilgenfeld, R., 2003. Coronavirus main proteinase (3CLpro): structure: basis for design of anti-SARS drugs. Science 300, 1763–1767.
Anderson, E.J., 2010. Prevention and treatment of viral diarrheal disease in pediatrics. Expert Rev. Anti Infect. Ther. 8, 205–217.
Asanaka, M., Atmar, R.L., Ruvelo, V., Crawford, S.E., Neill, F.H., Estes, M.K., 2005. Replication and packaging of Norwalk virus RNA in cultured mammalian cells. Proc. Natl. Acad. Sci. U.S.A.
Atmar, R.L., Opekun, A.R., Gilger, M.A., Estes, M.K., Crawford, S.E., Neill, F.H., Graham, D.Y., 2008. Norwalk virus shedding after experimental human infection. Emerg. Infect. Dis. 14, 1553–1557.
Bairoll, D., Karamichalis, K., Hsu, S., Chung, L.M., Reese, J., McFadden, N., Benson, A., Yarovinsky, F., Simmonds, P., Goodfellow, L., 2010a. Functional analysis of RNA structures present at the 3′ extremity of the murine norovirus genome: the variable polypyrimidine tract plays a role in viral virulence. J. Virol. 84, 2859–2870.
Bailey, D., Kaiser, W.J., Hollinshead, M., Moffat, K., Chaudhry, Y., Wileman, T., 2006. Lylation of the VPg protein of a human norovirus by its proteinase-polymerase precursor protein. Virolgy 347, 33–49.
Bailey, D., Karamichalis, K., Hsu, S., Chung, L.M., Reese, J., McFadden, N., Benson, A., Yarovinsky, F., Simmonds, P., Goodfellow, L., 2010a. Functional analysis of RNA structures present at the 3′ extremity of the murine norovirus genome: the variable polypyrimidine tract plays a role in viral virulence. J. Virol. 84, 2859–2870.
Bailey, D., Kaiser, W.J., Hollinshead, M., Moffat, K., Chaudhry, Y., Wileman, T., 2006. Lylation of the VPg protein of a human norovirus by its proteinase-polymerase precursor protein. Virolgy 347, 33–49.
Bailey, D., Kaiser, W.J., Hollinshead, M., Moffat, K., Chaudhry, Y., Wileman, T., 2006. Lylation of the VPg protein of a human norovirus by its proteinase-polymerase precursor protein. Virolgy 347, 33–49.
Bayliss, B.K., Cherney, M.M., Wang, M., Chen, L., Vannopoulos, C.G., Bilimoria, D., Nicolas, M., Bedard, J., Matsuara, T., 2005. Crystalline structures of the RNA dependent polymerase genotype 2a of hepatitis C virus reveal two conformations and suggest mechanisms of inhibition by non-nucleoside inhibitors. J. Biol. Chem. 280, 18202–18210.
Kapp, L.D., Lorsch, J.R., 2004. The molecular mechanics of eukaryotic translation. Annu. Rev. Biochem. 73, 657–704.

Karakashilis, L., Chaudhry, Y., Roberts, L.O., Goodfellow, I.G., 2006. Feline calicivirus replication: requirement for polyribosome tracting-binding protein is temperature-dependent. J. Gen. Virol. 87, 3337–3347.

Karl, S.M., Wobus, C.E., Lay, M., Davidson, J., Virgil, W.H.T., 2003. STAT1-dependent innate immunity to the Norwalk-like virus. Science 299, 1575-1578.

Katayama, H., Okuma, K., Furumai, H., Ohgaki, S., 2004. Series of surveys for enteric viruses and indicator organisms in Tokyo Bay after an event of combined sewer overflow. Water Sci. Technol. 50, 259–262.

Keswick, B.H., Satterwhite, T.K., Johnson, P.C., DuPont, H.L., Secor, S.L., Bittura, J.A., Carv, E.W., Hoff, V., 2005. Inactivation of Norwalk virus in drinking water by chlorine. Appl. Environ. Microbiol. 50, 261–264.

Kirkwood, C.D., Streitberg, R. 2008. Calicivirus shedding in children after recovery from diarrhoeal disease. J. Gen. Virol. 43, 346–348.

Koornman, C., On, M., Deuzer, E., 2004. Foodborne viruses: an emerging problem. Int. J. Food Microbiol. 90, 23–41.

Koornman, C., von Bonn, S., Vje, J. de, Medicci, D., Mone, S., 2002. Foodborne viruses. FEMS Microbiol. Rev. 26, 187–205.

Laurent, S., Vautherot, J.F., Le Gall, G., Madelaine, M.F., Rasschaert, D., 1997. Structural, antigenic and immunogenic relationships between European brown hare syndrome virus and rabbit haemorrhagic disease virus. J. Gen. Virol. 78 (Pt 11), 2803–2811.

Li, C.X., Parker, A., Menocal, E., Xiang, S., Bordolansky, L., Fruehau, J.H., 2006. Delivory of RNA interfering strategy. Virol. 357, 2103–2109.

Lin, C.H., Patton, J.G., 1995. Regulation of alternative 3′-UTR cleavage sites in the Southampton calicivirus polyprotein by expression of a CCR5 inhibitor gene suggesting triggered by a 7n m or nucleotide. Nucleic Acids Res. 33, 4527–4535.

Lindesmith, L., McE, C., Legrand, P., Flehrig, J.A., Trenier, J., Baric, R.S., 2005. Cellular and humoral immunity following Snow Mountain virus challenge. J. Virol. 79 (2005), 2014–2009.

Lindesmith, L., McE, C., Marionneau, S., Ruvoen, N., Jiang, X., Lindblad, L., Stewart, P., LePendu, J., Baric, R.S., 2003. Human susceptibility and resistance to Norwalk virus infection. Nat. Med. 9, 548–551.

Linden, Y., Yoder, E., Lindback, J., Wegscheider, M., Eiskson, Y., Tidestrom, L., Lagerquist-Width, A., Hedlund, K.O., Lofstad, S., Svensson, L., Norinder, A., 2001. A one-year study of foodborne illnesses in the municipality of Uppsala, Sweden. Emerg. Infect. Dis. 7, 588–593.

Liu, G., Chivato, J.S., Shi, Z., Choi, N.S., Merrick, W.C., Romo, R.E., Mone, C.L., Baric, R.S., 2006. Multivalent norovirus vaccines induce strong immune responses. J. Gen. Virol. 89, 693–698.

Liu, B.L., Viljoen, G.J., Clarke, L.N., Lambden, P.R., 1999. Identification of further proteolytically cleavable sites in the Southampoton calicivirus polyprotein by expression of the viral protease in E. coli. J. Gen. Virol. 80 (Pt 2), 291–296.

LoBue, A.D., Lindesmith, L., Yount, B., Harrington, P.R., Thompson, J.M., Johnstone, R.E., McE, C.L., Baric, R.S., 2006. Multivalent norovirus vaccines induce strong immune responses. J. Gen. Virol. 87 (2006), 5220–5234.

Lopman, B.A., Brown, D.W., Koopmans, M., 2002. Human caliciviruses in Europe. J. Clin. Virol. 22, 519–521.

Low, W.K., Dang, Y., Schneider-Poetsch, T., Shi, Z., Chui, N.S., Miseric, W.C., Romo, D., Liu, J.O., 2005. Inhibition of eukaryotic translation initiation by the marine calicivirus in Japan and Southeast Asia determined by radioimmunoassay. J. Virol. 81, 3251–3263.

Mitra, T., Souvovtsev, S.V., Green, K.Y., 2004. Mutagenesis of tyrosine 24 in the VPg protein is lethal for feline calicivirus. J. Virol. 78, 4931–4935.

Moseim, S.C., Chery, M.M., Mia, S., Plotz, S., James, M.N., 1997. Refined X-ray crystallographic structure of the poliovirus 3C proteinase. J. Mol. Biol. 273, 693–709.

Moss, S.R., Turner, S.L., Trout, R.C., White, P.J., Hudson, P.J., Desai, A., Armento, M., Forster, N.L., Guild, E.A., 2002. Molecular epidemiology of Rabbit haemorrhagic disease virus. J. Gen. Virol. 83, 2461–2467.

Muller, B., Kellen, U., Mas, M., Schleier, E., 2007. Genetic diversity and recombination of noroviruses in immunocompromised mice. Arch. Virol. 152, 1709–1719.

Mumperh, S.M., Changotra, H., Moore, T., Hessmann-Nichols, E.R., Wobus, C.E., Reilly, D.P., Moghadamfar, M., Shukla, D., Karst, S.M., 2007. Murine norovirus infection is associated with histopathological changes in immunocompeent hosts, but clinical disease is prevented by STAT1-dependent interferon responses. J. Virol. 81, 3251–3263.

Murata, T., Katsushina, H., Yagi, S., Muriy, S., Matsuzaki, Y., 2007. Prolonged norovirus shedding in infants <6 months of age with gastroenteritis. Pediart. Infect. Dis. J. 26, 46–49.

Nakamura, K., Soma, K., Kamikasa, T., Ueno, G., Yamamoto, M., Sato, T., Takeda, M., Nakata, H., Tanaka, T., Nakata, N., 2006. Norovirus VPg uridylylation. J. Biol. Chem. 281, 1032–1047.

Nagata, K., Sato, K., Tomita, R., Tanaka, T., 2008. Crystal structures of norovirus polymerase reveals the carboxyl terminus in the active site cleft. J. Virol. 82, 16638–16645.

Nakamura, K., Hardy, M.E., Nakata, S., Chiba, S., Estes, M.K., 1997. Molecular characterization of morphological typical human calicivirus Sapporo. Arch. Virol. 142, 1537–1552.

Oka, T., Hansman, G.S., Katayama, K., Ogawa, S., Nagata, N., Miyamura, T., Takeda, N., 2006. Expression of the VP2 protein of murine norovirus by a transient termination strategy. PLoS One 4 (Epub Dec 22).

Nelli, M.J., Meyer, R.F., Seals, B.S., 1998. The capsid protein of vesicular exanthema of swine virus serotype A4: relationship to the capsid protein of other animal caliciviruses. Virus Res. 54, 39–50.

Ng, K.K., Chery, M.M., Vazquez, A.L., Machin, A., Alonso, J.M., Parna, J., James, M.N., 2002. Crystal structures of active and inactive conformations of a caliciviral RNA-dependent RNA polymerase. J. Biol. Chem. 277, 1381–1387.

Ng, K.K., Berguedo, T., Nujo, J., Boga, J.A., Machin, A., Alonso, J.M., Parra, F., 2004. Crystal structure of norovirus polymerase reveals the carboxyl terminus in the active site cleft. J. Biol. Chem. 279, 16638–16645.

Oka, T., Katayama, K., Ogawa, S., Hansman, G.S., Kageyama, T., Miyamura, T., Takeda, N., 2005a. Cleavage activity of the sapovirus 3C-like protease in Escherichia coli. Arch. Virol. 150, 2539–2548.

Oka, T., Katayama, K., Ogawa, S., Hansman, G.S., Kageyama, T., Miyamura, T., Takeda, N., 2005b. Characterization of the unclassified bovine enteric virus Newbury agent-1 (Newbury1) and its potential hosts, but clinical disease is prevented by STAT1-dependent interferon response. J. Virol. 81, 3251–3263.
Proutski, V., Gritsun, T.S., Gould, E.A., Holmes, E.C., 1999. Biological consequences of deletions within the 3′ untranslated region of yellow fever virus: implications for virulence, attenuation and vaccine development. J. Gen. Virol. 72 (Pt 7), 1543–1549.

Proust, V., Gould, E.A., Holmes, E.C., 1997. Identification and genomic mapping of the ORF3 protein 2 forms a ternary complex with the 5′-untranslated region of yellow fever virus: implications for virulence, attenuation and vaccine development. J. Gen. Virol. 78 (Pt 7), 1543–1549.

Proust, V., Gould, E.A., Holmes, E.C., 1997b. Secondary structure of the 3′ untranslated region of flaviviruses: similarities and differences. Nucleic Acids Res. 25, 1194–1202.

Proust, V., Gritsun, T.S., Gould, E.A., Holmes, E.C., 1999. Secondary structure of the 3′-untranslated region of yellow fever virus. J. Gen. Virol. 80, 386–389.

Proust, V., Gritsun, T.S., Gould, E.A., Holmes, E.C., 1999b. Biological consequences of deletions within the 3′-untranslated region of flaviviruses may be due to rearrangements of RNA secondary structure. Virus Res. 64, 107–123.

Radford, A.D., Dawson, S., Porter, C.J., Gaskell, R.M., 2007. Feline calicivirus. Vet. Microbiol. 73, 281–300.

Pelkmans, L., Helenius, A., 2003. Insider information: what viruses tell us about endocytic Curr. Opin. Cell Biol. 15, 414–422.

Pelletier, J., Sonenberg, N., 1998. Internal initiation of translation of eukaryotic mRNAs directed by a sequence derived from poliovirus RNA. Nature 334, 320–325.

Pfister, T., Wimmer, E., 2001. Polypeptide p41 of a Norwalk-like virus is a nucleic acid binding domain of a nucleating envelope protein. J. Virol. 75, 1611–1619.

Pan, T.G., Okutsko, S., Muller, W.E., Kohno, H., Ushijima, H., 2006. Novel recombinant sapovirus, Japan. Emerg. Infect. Dis. 12, 865–867.

Povey, R.C., 1978a. Effect of orally administered ribavirin on experimental feline calicivirus infection in cats. J. Am. Vet. Med. Assoc. 172, 1337–1341.

Povey, R.C., 1978b. In vivo antiviral efficacy of ribavirin against feline calicivirus, feline viral rhinotracheitis virus, and canine parainfluenza virus. Am. J. Vet. Res. 39, 175–178.

Povy, T.A., Kaminoki, A., Connell, E.J., Fraser, C.S., Jackson, R.J., 2007. The mechanism of an exceptional case of reinfection after a long ORF REVIF protects why such events do not generally occur in mammalian mRNA translation. Genes Dev. 21, 3149–3162.

Prouts, V., Gaunt, M.W., Gould, E.A., Holmes, E.C., 1997a. Secondary structure of the 3′-untranslated region of yellow fever virus: implications for virulence, attenuation and vaccine development. J. Gen. Virol. 78 (Pt 7), 1543–1549.

Prouts, V., Gould, E.A., Holmes, E.C., 1997b. Secondary structure of the 3′-untranslated region of flaviviruses: similarities and differences. Nucleic Acids Res. 25, 1194–1202.

Prouts, V., Gritsun, T.S., Gould, E.A., Holmes, E.C., 1999. Biological consequences of deletions within the 3′-untranslated region of flaviviruses may be due to rearrangements of RNA secondary structure. Virus Res. 64, 107–123.

Radford, A.D., Coyne, K.P., Dawson, S., Porter, C.J., Gaskell, R.M., 2007. Feline calicivirus. Vet. Microbiol. 73, 281–300.

Radford, A.D., Dawson, S., Coyne, K.P., Porter, C.J., Gaskell, R.M., 2006. The challenge for the next generation of feline calicivirus vaccines. Vet. Microbiol. 117, 14–18.

Reuter, G., Farkas, T., Berke, T., Jiang, X., Matson, D.O., Szucs, G., 2002. Molecular and biological characterization of the murine norovirus nonstructural polyprotein in infected cells. J. Virol. 76, 8018–8031.

Rockx, B.H., Vennema, H., Hoebe, C.J., Duizer, E., Koopmans, M.P., 2005. Association of hst0 group B antigens and susceptibility to norovirus infections. J. Infect. Dis. 191, 749–754.

Rohayem, J., Langer, K., Robel, I., Scheffler, U., Temme, A., Rudolph, W., 2006a. Characterization of norovirus 3Dpol RNA-dependent RNA polymerase activity and initiation of RNA synthesis. J. Gen. Virol. 87, 2621–2630.

Rohayem, J., Munch, J., Rethwilm, A., 2005. Evidence of recombination in the norovirus capsid gene. J. Virol. 79, 4977–4990.

Rohayem, J., Robel, I., Langer, K., Scheffler, U., Rudolph, W., 2006b. Protein-primed and de novo initiation of RNA synthesis by norovirus 3Dpol. J. Virol. 80, 7060–7069.

Rossen, J.F., El-Gohary, Y.M., 2006. Nitroxide in the treatment of viral gastroenteritis: a randomized double-blind placebo-controlled clinical trial. Aliment Pharmacol. Ther. 24, 1423–1430.

Rydel, C.E., Nilsson, J., Rodriguez-Diaz, J., Ruveen-Clouet, N., Svensson, L., Le Pendu, J., Larson, G., 2009. Norovirus genotypes recognize siaI/Lewis x/neoglycoprotein. Glycobiology 19, 309–320.

Sakuma, Y., Chiba, S., Kogasaka, R., Terashima, H., Nakamura, S., Horino, K., Nakao, T., 1981. Prevalence of antibody to human calicivirus in general population of the Japan. J. Virol. 33, 211–225.

Scheffler, U., Rudolph, W., Gebhardt, J., Rohayem, J. 2007. Differential cleavage of the norovirus polyprotein precursor by two active forms of the viral protease. J. Virol. 81, 4012–4024.

Stuart, A.D., Brown, T.D., 2006. Entry of feline calicivirus is dependent on clathrin-mediated endocytosis and acidification in endosomes. J. Virol. 80, 7060–7072.

Stein, D.A., 2008. Infection of norovirus RNA with peptide-conjugated mor- pholino oligonucleotides. Curr. Pharm. Des. 14, 2619–2634.

Stein, D.A., Huang, C.Y., Silengo, S., Amantana, A., Crumley, S., Blouch, R.E., Iversen, P.L., Kinney, R.M., 2008. Treatment of AG129 mice with antisense morpholino oligomers increases survival time following challenge with dengue 2 virus. J. Antimicrob. Chemother. 62, 555–565.

Stein, D.A., Shi, P.Y., 2008. Nucleic acid-based inhibition of flavivirus infections. Front. Biosci. 13, 1385–1395.

Straub, T.M., Honer zu Bentrup, K., Orosz-Coghlan, P., Dohnalkova, A., Mayer, B.K., Bartholomew, R.A., Valdez, C.O., Bruckner-Lea, C.J., Gerba, C.P., Abbaszadegan, M., Nickerson, C.A., 2007. In vitro cell culture infectivity assay for human noroviruses. Emerg. Infect. Dis. 13, 399–405.

Stuart, A.D., Brown, T.D., 2006. Entry of feline calicivirus is dependent on clathrin-mediated endocytosis and acidification in endosomes. J. Virol. 80, 7500–7509.

Sowdloff, D.L., 2002. PAUP, Phylogenetic Analysis Using Parsimony (and other methods). Sinauer Associates, Sunderland.

Tacket, C.O., Mason, H.S., Losonsky, G., Estes, M.K., Levine, M.M., Arztzen, C.J., 2000. Human immune responses to a novel norwalk virus vaccine delivered in transgenic potatoes. J. Infect. Dis. 182, 302–305.

Tan, M., Tanaka, N., Natori, K., Ikerd, D.L., Losonsky, G., Takeda, N., 2004. Genogroup II noroviruses efficiently bind to heparan sulfate proteoglycan associated with the cellular membrane. J. Virol. 78, 3817–3826.

Tan, M., Xia, M., Chen, Y., Bu, W., Hegde, R.S., Meller, J., Li, X., Jiang, X., 2009. Conservation of carbohydratebinding sites: evidence of human HIBCA selection in norovirus evolution. PLoS One 4, e5058 (Epub 2009 Apr 1).

Tan, M., Huang, P., Meller, J., Zhong, W., Farkas, J., Jiang, X., 2003. Mutations within the F2 domain of norovirus capsid affect binding to human hsto-blood group antigens: evidence for a binding pocket. J. Virol. 77, 12622–12627.
